



XLIX Reunión Anual SAB

1 al 3 de diciembre 2021





Sociedad Argentina de Biofísica

XLIX Reunión Anual SAB / compilación de José María Delfino ... [et al.]. - 1a ed. - Ciudad Autónoma de Buenos Aires: SAB - Sociedad Argentina de Biofísica, 2021.

Libro digital, PDF

Archivo Digital: descarga y online

ISBN 978-987-27591-9-3

1. Biofísica. 2. Investigación Experimental. I. Delfino, José María, comp. II. Título.

CDD 571.4

Diagramación y Edición

M. Soledad Celej, Irene Mangialavori

Diseño de Tapa y Logo

Comité organizador

Asistencia Técnica

Juan Pablo Acierno

Quedan prohibidos, dentro de los límites establecidos en la ley y bajo apercibimiento legalmente previsto, la reproducción total o parcial de esta obra por cualquier medio o procedimientos ya sea electrónico o mecánico, el tratamiento informático, el alquiler o cualquiera otra forma de cesión de la obra sin la autorización previa y por escrito de los titulares del *copyright*.

Sociedad Argentina de Biofísica

Member of the International Union for Pure and Applied Biophysics



XLIX Reunión Anual SAB

1-3 de diciembre de 2021

Argentina

XLIX Annual Meeting SAB

1-3 December 2021

Argentina



SAB Executive, Organizing and Scientific Committee

President

José María Delfino

IQUIFIB-CONICET, FFyB-UBA, Buenos Aires

Vicepresident

M. Soledad Celej

CIQUIBIC-CONICET, FCQ-UNC, Córdoba

Past President

Lía Pietrasanta

IFIBA-CONICET, FCEN-UBA, Buenos Aires

Secretary

Ernesto Ambrogio

CIQUIBIC-CONICET, FCQ-UNC, Córdoba

Treasurer

Noelia Burgardt

IQUIFIB-CONICET, FFyB-UBA, Buenos Aires

Board members

César Ávila

IMMCA-CONICET, FBQyF-UNT, San Miguel de Tucumán

Axel Hollmann

CIBAAL-CONICET, UNSE, Santiago del Estero

Irene Mangialavori

IQUIFIB-CONICET, FFyB-UBA, Buenos Aires

Santiago Di Lella

IQUIBICEN-CONICET, FCEyN-UBA, Buenos Aires

New functional caffeine analogs as possible multitarget potentiators of the cholinergic system

Munafó JP^a, Fabiani C^a, Biscussi B^b, Murray AP^b, Antollini SS^a

a - Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB). Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (UNS- CONICET), Bahía Blanca, Argentina

b - INQUISUR (CONICET-UNS)-Instituto de Química del Sur

Since cholinergic deficit is characteristic of Alzheimer's disease, two possible molecular targets for its treatment are the acetylcholinesterase (AChE) and the nicotinic acetylcholine receptors (nAChRs). In previous studies of our group, we found that caffeine behaves as an agonist of the nAChRs and confirmed that it inhibits the AChE. We subsequently synthesized hybrid caffeine analogs by connecting a theophylline group with a pyrrole group via a carbon linker of different lengths (3 to 7 carbon atoms). All the compounds inhibited the AChE and activated the nAChR with higher potency than caffeine. Some of them conduct the receptor to a desensitized and agonist-refracting state, while others make the receptor quickly return to a resting, agonist-responding state. Based on these results, in this work we synthesized three new hybrid analogs of the synthetic compound with a linker of 5 carbon atoms, which belongs to the desensitizing group, maintaining the theophylline structure but changing the pyrrole group by piperidine, 1-methylpiperazine or dimethylamine. All analogs inhibited the AChE with higher potency than the precursor. Using Crystal violet (CrV) fluorescence probe, an open channel blocker with higher affinity for the desensitized than for the resting state of the nAChR, we observed that the compounds with piperidine and 1-methylpiperazine caused nAChR conformational changes that could be related to a conformational transition corresponding to receptor activation followed by a stabilization in the desensitized state. In contrast, the compound with the dimethylamine group did not conduct the nAChR to a desensitized state. Our results provide new insights into structure-activity relationship for this group of functional multi-target drugs giving valuable tools to transform the search of new drugs from random screening into a detailed rational drug design of new interventional therapies in neurological diseases.